|
Days after the start of administration
|
-1
|
14
|
28
|
42
|
56
|
|---|
|
Nuclear cell count (× 104/μL)
|
6.0
|
7.0
|
10.0
|
12.0
|
4.0
|
|
Blast+Promyelocyte (%)
|
5.8
|
17.8
|
0.8
|
1.2
|
0.6
|
|
Myeloid (%)
|
51.2
|
32.6
|
29.4
|
21.6
|
34.2
|
|
Erythroid (%)
|
22.6
|
28.8
|
55.0
|
70.0
|
33.2
|
|
Others (%)
|
20.4
|
20.8
|
14.8
|
7.2
|
32.0
|
|
PML-RARα FISH (%)
|
5.0
|
83.0
|
33.0
|
9.0
|
0.0
|
|
CD11b (%)
|
5.0
|
27.0
|
43.2
|
59.3
|
ND
|
|
CD15 (%)
|
8.6
|
23.2
|
38.5
|
47.2
|
ND
|
|
CD117 (%)
|
94.5
|
30.4
|
41.3
|
23.9
|
ND
|
|
CD34 (%)
|
38.0
|
14.4
|
26.2
|
15.8
|
ND
|
- BM aspirations were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. Response assessment was evaluated by BM aspirate examination, FISH analysis and the expression levels of cell surface markers. ND: no data.
